Objective Although the underlying cause of Huntington's disease (HD) is well established,
the actual pathophysiological processes involved remain to be fully elucidated. In other …

The blood‐brain barrier (BBB) prevents the majority of drugs from crossing into the brain
and reaching neurons. To overcome this challenge, safe and non‐invasive technologies …

Monoclonal antibodies (mAbs) targeting blood–brain barrier (BBB) transporters are being
developed for brain drug targeting. However, brain uptake quantification remains a challenge, …

The transferrin receptor (TfR) is highly expressed by brain capillary endothelial cells (BCECs)
forming the blood–brain barrier (BBB) and is therefore considered as a potential target for …

Human apolipoprotein E (APOE) exists in three isoforms ε2, ε3, and ε4, of which APOE4 is
the main genetic risk factor of Alzheimer's disease (AD). As cerebrovascular defects are …

Intravenous immunoglobulin (IVIg) is currently evaluated in clinical trials for the treatment of
various disorders of the central nervous system. To assess its capacity to reach central …

Benefits on cognition from docosahexaenoic acid ( DHA , 22 : 6 n‐3) intake are absent in
humans carrying apolipoprotein E ε4 allele ( APOE 4), the most important genetic risk factor for …

We evaluated the integrity and function of the blood–brain barrier in 3xTg-AD mice aged 3–18
months and in APP/PS1 mice aged 8-months to determine the impacts of changes in …

The involvement of transporters located at the blood-brain barrier (BBB) has been suggested
in the control of cerebral Aβ levels, and thereby in Alzheimer’s disease (AD). However, little …

Evidences suggest that omega-3 fatty acid (n-3 PUFA) metabolism is imbalanced in apolipoprotein
E epsilon 4 isoform carriers (APOE4). This study aimed to investigate APOE genotype…